2025-05-14 - Analysis Report
Okay, here's a report analyzing Teva Pharmaceutical Industries Ltd ADR (TEVA) based on the provided data.

**TEVA (Teva Pharmaceutical Industries Ltd ADR) Analysis**

Teva Pharmaceutical Industries Ltd. ADR is a global pharmaceutical company that develops, manufactures, and markets generic and specialty medicines.

**1. Performance vs. S&P 500 (VOO)**

*   **TEVA Cumulative Return:** 61.68%
*   **VOO Cumulative Return:** 81.82%
*   **Absolute Divergence (Current):** -20.14%
*   **Divergence Range:** Max: 21.9%, Min: -122.3%
*   **Relative Divergence:** 70.9%

**Analysis:** TEVA has underperformed the S&P 500 by 20.14% cumulatively.  The relative divergence of 70.9% indicates that the current divergence is in the upper range of its historical divergence, suggesting that TEVA is performing relatively closer to the S&P 500 than it has in the past.

**Alpha/Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha  | Beta  | Cap(B) |
|------------|----------|-------|--------|-------|--------|
| 2015-2017  | -44.0%   | 58.4% | -73.0% | -0.0  | 21.7   |
| 2016-2018  | -41.0%   | 70.4% | -59.0% | -0.1  | 17.7   |
| 2017-2019  | -16.0%   | 70.4% | -45.0% | -0.2  | 11.2   |
| 2018-2020  | 0.0%    | 70.4% | -25.0% | -0.2  | 11.1   |
| 2019-2021  | -22.0%   | 58.3% | -76.0% | -0.2  | 9.2    |
| 2020-2022  | 27.0%    | 74.8% | 20.0%  | -0.2  | 10.5   |
| 2021-2023  | 38.0%    | 74.8% | 21.0%  | -0.8  | 12.0   |
| 2022-2024  | 122.0%   | 74.8% | 106.0% | -0.7  | 25.3   |
| 2023-2025  | 72.0%   | 76.0% | 42.0% | 0.1  | 20.1   |

**Analysis:**

*   **CAGR:** Shows inconsistent performance with periods of significant negative and positive growth. Recent periods (2022-2024, 2023-2025) show strong positive growth.
*   **MDD:** High Maximum Drawdown (MDD) values indicate significant risk and volatility in TEVA's returns.
*   **Alpha:** Mostly negative Alpha values suggest underperformance relative to the market, though recent years (2020-2025) show positive Alpha.
*   **Beta:** Generally low to negative Beta values suggest TEVA has been less sensitive to market movements, and recently Beta values are more volatile.
*    **Cap(B):** Market Cap increased over time

**2. Recent Stock Price Movement**

*   **Current Price:** 17.48
*   **Previous Close:** 17.96
*   **Change:** -2.67% (Significant drop)
*   **5-day Moving Average:** 17.608
*   **20-day Moving Average:** 15.517
*   **60-day Moving Average:** 15.5872

**Analysis:** The stock price has recently declined significantly (-2.67%). The current price is below the 5-day moving average but above the 20-day and 60-day moving averages, suggesting a recent pullback within a potentially upward trend.

**3. Market Risk Indicators**

*   **Market Risk Indicator (MRI):** 0.348 (Low Risk)
*   **RSI:** 72.43 (Overbought)
*   **PPO:** 1.98 (Positive)
*   **20-day Relative Divergence Change:** 2.7% (Short-term increase)
*   **Expected Return:** -32.0%

**Analysis:**

*   The MRI indicates a low-risk environment.
*   The RSI indicates that the stock is overbought and may be due for a correction.
*   The PPO is positive, suggesting an upward trend.
*   The recent increase in relative divergence suggests short-term outperformance relative to the S&P 500.
*   The negative expected return indicates potential underperformance relative to the S&P 500 over the long term (2+ years) for new investments made at this time.
*   The significant price change warrants caution and further investigation into potential catalysts.

**4. Recent News & Significant Events**

*   **2025-05-14:**  Major business developments, regulatory changes, or market events.
*   **2025-05-13:**  Analysts discussing recent performance and outlook.
*   **2025-05-11:**  Notable volatility influenced by news, earnings, or executive actions.
*   **2025-05-12:** Market experts highlight risks and opportunities.

**Analysis:** The news suggests recent volatility and potential key events influencing the stock. Investors should closely monitor news and company announcements.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출      |
|------------|--------|-----------|
| 2025-05-07 | 0.19   | 3.89 B$   |
| 2024-11-06 | -0.39  | 4.33 B$   |
| 2024-07-31 | -0.75  | 4.16 B$   |
| 2024-05-08 | -0.12  | 3.82 B$   |
| 2025-05-07 | -0.12  | 3.82 B$   |

**Analysis:**  Earnings per share (EPS) has been inconsistent, with both positive and negative values. Revenue has fluctuated within a relatively narrow range. The latest EPS is positive, which is a positive signal. It's important to understand the reasons behind the volatility in EPS.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-03-31 | $3.89B    | 48.24%        |
| 2024-12-31 | $4.23B    | 50.15%        |
| 2024-09-30 | $4.33B    | 49.60%        |
| 2024-06-30 | $4.16B    | 48.61%        |
| 2024-03-31 | $3.82B    | 46.37%        |

**Capital and Profitability**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-03-31 | $6.26B    | 3.42%     |
| 2024-12-31 | $5.37B    | -4.04%    |
| 2024-09-30 | $6.07B    | -7.21%    |
| 2024-06-30 | $6.36B    | -13.30%   |
| 2024-03-31 | $7.28B    | -1.91%    |

**Analysis:** Revenue has been relatively stable. Profit margins have remained strong, around 48% - 50%, which is generally healthy for a pharmaceutical company. Equity has fluctuated, and the return on equity (ROE) has been highly variable, with recent improvement.

**7. Overall Assessment**

TEVA presents a mixed picture. While recent performance has shown some positive signs, there are still significant risks and uncertainties.

*   **Positives:**
    *   Recent positive EPS and revenue stability.
    *   Strong profit margins.
    *   Low Market Risk Indicator
    *   Recent periods of positive Alpha

*   **Negatives/Concerns:**
    *   Historical underperformance relative to the S&P 500.
    *   High historical volatility (MDD).
    *   Inconsistent EPS.
    *   Negative long-term expected return relative to the S&P 500.
    *   Recent significant stock price drop.

**Recommendation:**  Given the overbought RSI, the recent price drop, and negative expected return, caution is warranted. Investors should closely monitor news, earnings, and company announcements to assess the potential for future growth. A deeper dive into the reasons for the fluctuating EPS and volatility in ROE is recommended.

